HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lavee, J. Articles by Mohr, R. Search for Related Content PubMed PubMed Citation Articles by Lavee, J. Articles by Mohr, R.

The Annals of Thoracic Surgery, Vol 55, 114-119, Copyright © 1993 by The Society of Thoracic Surgeons

ARTICLES

Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study

J Lavee, Z Raviv, A Smolinsky, N Savion, D Varon, DA Goor and R Mohr
Department of Cardiac Surgery, Maurice and Gabriela Goldschleger Eye Institute, Tel Hashomer, Israel.

To evaluate the effect of low-dose aprotinin during cardiopulmonary bypass on platelet function and clinical hemostasis, 30 patients undergoing various cardiopulmonary bypass procedures employing bubble oxygenators were randomized to receive either low-dose aprotinin (2 x 10(6) KIU in the cardiopulmonary bypass priming solution, 15 patients [group A]) or placebo (15 patients [group B]). Blood samples were collected before and after cardiopulmonary bypass to assess platelet count and aggregation on extracellular matrix, which was studied by a scanning electron microscope. On a scale of 1 to 4 preoperative mean platelet aggregation grades were similar in both groups (3.8 +/- 0.5 and 3.5 +/- 0.5 for groups A and B, respectively). Postoperatively, platelet aggregation on extracellular matrix decreased slightly in group A (2.8 +/- 1.3; p < 0.01) and significantly in group B (1.3 +/- 0.5; p < 0.001). Eleven of the 15 patients in group A remained in aggregation grade 3 or 4 compared with none of the group B patients. Platelet count was similar in both groups preoperatively and postoperatively. Total 24-hour postoperative bleeding and blood requirement were lower in the aprotinin group (487 +/- 121 mL and 2.3 +/- 1.0 units) than in the placebo group (752 +/- 404 mL and 6.8 +/- 5.1 units; p < 0.01). These results show that the use of low-dose aprotinin during cardiopulmonary bypass provides improved postoperative hemostasis, which might be related to the protection of the platelet aggregating capacity.

This article has been cited by other articles:

				G. Lindvall, U. Sartipy, and J. van der Linden Aprotinin Reduces Bleeding and Blood Product Use in Patients Treated With Clopidogrel Before Coronary Artery Bypass Grafting Ann. Thorac. Surg., September 1, 2005; 80(3): 922 - 927. [Abstract] [Full Text] [PDF]

				R. H. Hongo, J. Ley, S. E. Dick, and R. R. Yee The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting J. Am. Coll. Cardiol., July 17, 2002; 40(2): 231 - 237. [Abstract] [Full Text] [PDF]

				L. Shore-Lesserson Monitoring the Hematologic Complications of Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 207 - 216. [Abstract] [PDF]

				H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF]

				E. J Fransen, D. S de Jong, W. T. Hermens, and J. G Maessen Is postoperative blood loss, loss of blood? A pilot study in cardiac surgical patients Perfusion, July 1, 2001; 16(4): 301 - 308. [Abstract] [PDF]

				S. C. Silvestry and P. K. Smith Current status of cardiac surgery in the abciximab-treated patient Ann. Thorac. Surg., August 1, 2000; 70(2): S12 - 19. [Abstract] [Full Text] [PDF]

				S. A. Kozek-Langenecker, S. F. Mohammad, T. Masaki, W. Green, C. Kamerath, and A. K. Cheung The Effects of Aprotinin on Platelets In Vitro Using Whole Blood Flow Cytometry Anesth. Analg., January 1, 2000; 90(1): 12 - 12. [Abstract] [Full Text] [PDF]

				C. J. O’Connor, D. V. Brown, M. Avramov, S. Barnes, H. N. O’Connor, and K. J. Tuman The Impact of Renal Dysfunction on Aprotinin Pharmacokinetics During Cardiopulmonary Bypass Anesth. Analg., November 1, 1999; 89(5): 1101 - 1101. [Abstract] [Full Text] [PDF]

				J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF]

				M. J. Ray, BAppSc, N. A. Marsh, S. J. E. Just, BAppSc, E. J. Perrin, BAppSc, M. F. O'Brien, and G. A. T. Hawson Preoperative Platelet Dysfunction Increases the Benefit of Aprotinin in Cardiopulmonary Bypass Ann. Thorac. Surg., January 1, 1997; 63(1): 57 - 63. [Abstract] [Full Text]

				S. Ashraf, Y. Tian, D. Cowan, U. Nair, R. Chatrath, N. R. Saunders, K. G. Watterson, and P. G. Martin ""Low-Dose"" Aprotinin Modifies Hemostasis but Not Proinflammatory Cytokine Release Ann. Thorac. Surg., January 1, 1997; 63(1): 68 - 73. [Abstract] [Full Text]

				G. E. Hill, A. Alonso, J. R. Spurzem, A. H. Stammers, and R. A. Robbins APROTININ AND METHYLPREDNISOLONE EQUALLY BLUNT CARDIOPULMONARY BYPASS-INDUCED INFLAMMATION IN HUMANS J. Thorac. Cardiovasc. Surg., December 1, 1995; 110(6): 1658 - 1662. [Abstract] [Full Text]

				Z. A Varga Autologous plateletpheresis in cardiac surgery Perfusion, November 1, 1993; 8(6): 471 - 476. [Abstract] [PDF]